浏览全部资源
扫码关注微信
神经丝轻链蛋白在阿尔茨海默病早期诊断中的作用研究
Role of neurofilament light chain protein in the early diagnosis of Alzheimer's disease
- 重庆医科大学学报 2021年46卷第11期 页码：1355-1359
- 作者机构：
新疆医科大学附属中医医院神经内科，乌鲁木齐 830000
- 作者简介：
[ "麦尔哈巴·赛里木，Email：849124908@qq.com，研究方向：痴呆与认知障碍性疾病。" ]
孟新玲，研究生，硕导，副教授，新疆医科大学附属中医医院脑病一科主任。中华中医药学会脑病分会常务委员、国家卫健委脑卒中防治工程专家委员会中西医结合专业委员会常务委员、中国中医药研究促进会中西医结合脑病防治与康复专业委员会副主任委员、中国医师协会神经内科分会神经免疫学组委员、中国医师协会神经修复专业委员会神经变性与修复学组委员、中华医学会神经病学分会痴呆与认知障碍学组委员、中国中西医结合学会神经科专业委员会委员、中国老年保健协会老年痴呆及相关疾病专业委员会（ADC）委员、中国老年医学学会认知障碍分会（ACDC）神经心理量表评估学术工作委员会委员，中国康复医学会帕金森病与运动障碍专业委员会委员、西北地区hhc认知学院副院长、新疆医学会神经病学专业委员会副主任委员、新疆医学会神经病学专业委员会痴呆与认知障碍学组组长。主持和参加国家自然基金课题、新疆自治区自然基金项目、新疆科技支疆项目、新疆医科大学校级教改项目及“十一五”“十二五”国家科技支撑计划项目，主持和参加20项临床药物研究课题，在医学期刊发表学术论文数十篇，出版学术专著1部，申请专利1项。Email：altmxl@126.com。
- 基金信息：新疆自治区自然科学基金资助项目(2017D01C153)
DOI：10.13406/j.cnki.cyxb.002914
中图分类号： R741纸质出版日期：2021-11-28，
收稿日期：2021-07-04，
扫 描 看 全 文
赛里木麦尔哈巴·, 郭晨晨, 张清瑜, 等. 神经丝轻链蛋白在阿尔茨海默病早期诊断中的作用研究[J]. 重庆医科大学学报, 2021,46(11):1355-1359.
Maierhaba· Sailimu, Chenchen Guo, Qingyu Zhang, et al. Role of neurofilament light chain protein in the early diagnosis of Alzheimer's disease[J]. Journal of Shanxi Agricultural Sciences, 2021,46(11):1355-1359.
赛里木麦尔哈巴·, 郭晨晨, 张清瑜, 等. 神经丝轻链蛋白在阿尔茨海默病早期诊断中的作用研究[J]. 重庆医科大学学报, 2021,46(11):1355-1359. DOI： 10.13406/j.cnki.cyxb.002914.
Maierhaba· Sailimu, Chenchen Guo, Qingyu Zhang, et al. Role of neurofilament light chain protein in the early diagnosis of Alzheimer's disease[J]. Journal of Shanxi Agricultural Sciences, 2021,46(11):1355-1359. DOI： 10.13406/j.cnki.cyxb.002914.
摘要
目的：
2
探讨血清神经丝轻链蛋白（neurofilament light chain protein，NFL）是否可以作为预测阿尔茨海默病（Alzheimer's disease，AD）早期的外周血生物标志物。
方法：
2
纳入新疆医科大学附属中医医院阿尔茨海默病临床数据库的AD患者50例，遗忘型轻度认知功能障碍（amnestic mild cognitive impairment，aMCI）患者50例，以及选择同一时间段内按年龄、文化程度相匹配的健康对照者（cognitively normal，CN）50例，受试者均采集血清，采用酶联免疫吸附试验（enzyme linked immunosorbent assay，ELISA）检测血清NFL水平。
结果：
2
①AD、aMCI与CN患者的年龄、教育年限、体质指数（body mass index，BMI）比较均无统计学差异（
P
>
0.05），资料具有可比性。②AD患者简易精神状态检查量表（mini-mental state examination，MMSE）、蒙特利尔认知评估量表（Montreal cognitive assessment，MoCA）评分显著低于aMCI组和CN组[AD组（17.48±7.50），aMCI组（25.56±1.63），CN组（28.60±1.09）；
F
=81.830，
P
=0.000]，MoCA评分差异最明显[AD组（12.04±6.31），aMCI组（19.92±3.17），CN组（27.62±1.16）；
F
=177.187，
P
=0.000]。③血清NFL水平[AD组（4.486±2.463）ng/mL，aMCI组（5.101±2.172）ng/mL，CN组（2.885±1.469）ng/mL，
F
=15.167，
P
=0.000]，AD组和aMCI组NFL水平显著高于CN组，其中aMCI组最高，3组间比较具有统计学差异；应用Spearman相关性分析发现3组间年龄、MMSE评分、MoCA评分、日常生活能力量表评分（activity of dai1y living scale，ADL）、临床痴呆评定量表（clinical dementia rating，CDR）评分与NFL水平没有相关性（
P
>
0.05）。
结论：
2
轻度认知功能障碍患者血清NFL水平最高，提示血清NFL也许是预测阿尔茨海默病早期的外周血生物标志物。
Abstract
Objective
:
2
To explore whether serum neurofilament light chain protein (NFL) can be used as a peripheral blood biomarker to predict the early stage of Alzheimer's disease (AD).
Methods
:
2
The study included 50 AD patients (AD group) from the Alzheimer's disease clinical database of the Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University
50 patients with amnestic mild cognitive impairment (aMCI group) and the same time period 50 cognitively normal controls (CN group) matched by age and educational level. The subjects were all collected serum and detected the serum NFL protein level by enzyme linked immunosorbent assay (ELISA).
Results
:
2
①The AD group
aMCI group and CN group had no statistical difference in age
education years and BMI (
P
>
0.05)
and the data were comparable. ②AD patients MMSE score was significantly lower than that of aMCI group and CN group [AD group (17.48±7.50)
aMCI group (25.56±1.63)
CN group (28.60±1.09);
F
=81.830
P
=0.000]. The MoCA score had the most significant difference [AD group (12.04±6.31)
aMCI group (19.92±3.17)
CN group (27.62±1.16);
F
=177.187
P
=0.000]. ③The NFL protein level of AD group and aMCI group were significantly higher than that of CN group
among which aMCI group was the highest [AD group (4.486±2.463) ng/mL
aMCI group (5.101±2.172) ng/mL and CN group (2.885±1.469) ng/mL
F
=15.167
P
=0.000]. Spearman correlation analysis found that age
MMSE score
MoCA score
ADL score and CDR score were not correlated with NFL protein levels among the three groups (
P
>
0.05).
Conclusion
:
2
Serum NFL levels in patients with MCI is the highest
suggesting that serum NFL level may be a peripheral blood biomarker for predicting the early stage of AD.
关键词
神经丝轻链蛋白阿尔茨海默病轻度认知功能障碍
Keywords
neurofilament light chain proteinAlzheimer's diseasemild cognitive impairment
references
Lewczuk P, Ermann N, Andreasson U, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease[J]. Alzheimers Res Ther, 2018, 10(1):71.
Jia LF, Du YF, Chu L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study[J]. Lancet Public Health, 2020, 5(12):e661-e671.
Rohrer JD, Woollacott IO, Dick KM, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia[J]. Neurology, 2016, 87(13):1329-1336.
Zetterberg H, Skillbäck T, Mattsson N, et al. Association of cerebrospinal fluid neurofilament light concentration with alzheimer disease progression[J]. JAMA Neurol, 2016, 73(1):60-67.
Zhou WJ, Zhang J, Ye FL, et al. Plasma neurofilament light chain levels in Alzheimer's disease[J]. Neurosci Lett, 2017, 650:60-64.
Mattsson N, Cullen NC, Andreasson U, et al. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease[J]. JAMA Neurol, 2019, 76(7):791-799.
Laser-Azogui A, Kornreich M, Malka-Gibor E, et al. Neurofilament assembly and function during neuronal development[J]. Curr Opin Cell Biol, 2015, 32:92-101.
Håkansson I, Tisell A, Cassel P, et al. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis[J]. J Neuroinflammation, 2018, 15(1):209.
Yu RQ, Topiwala A, Jacoby R, et al. Aggressive behaviors in Alzheimer disease and mild cognitive impairment: systematic review and Meta-analysis[J]. Am J Geriatr Psychiatry, 2019, 27(3):290-300.
Mariotto S, Farinazzo A, Magliozzi R, et al. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies[J]. J Peripher Nerv Syst, 2018, 23(3):174-177.
Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases[J]. PLoS One, 2013, 8(9):e75091.
Varhaug KN, Torkildsen Ø, Myhr KM, et al. Neurofilament light chain as a biomarker in multiple sclerosis[J]. Front Neurol, 2019, 10:338.
Kuhle I, Gaiottino J, Leppert D, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome[J]. J Neurol Neurosurg Psychiatry, 2015, 86(3):273-279.
Basal E, Zalewski N, Kryzer TJ, et al. Paraneoplastic neuronal intermediate filament autoimmunity[J]. Neurology, 2018, 91(18):e1677-e1689.
Howett D, Castegnaro A, Krzywicka K, et al. Differentiation of mild cognitive impairment using an entorhinal cortex-based test of virtual reality navigation[J]. Brain, 2019, 142(6):1751-1766.
Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders[J]. Nat Rev Neurol, 2018, 14(10):577-589.
Gisslén M, Price RW, Andreasson U, et al. Plasma concentration of the neurofilament light protein(NFL)is a biomarker of CNS injury in HIV infection: a cross-sectional study[J]. EBioMedicine, 2016, 3:135-140.
Seelaar H, Rohrer JD, Pijnenburg YAL, et al. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review[J]. J Neurol Neurosurg Psychiatry, 2011, 82(5):476-486.
Rana OR, Schröder JW, Baukloh JK, et al. Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest[J]. Int J Cardiol, 2013, 168(2):1322-1327.
Rissin DM, Kan CW, Campbell TG, et al. Single-molecule enzymelinked immunosorbent assay detects serum proteins at subfemtomolar concentrations[J]. Nat Biotechnol, 2010, 28(6):595-599.
0
浏览量
0
下载量
0
CSCD
- 网络PDF下载
- XML下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
